Pacira Pharmaceuticals Inc. (PCRX) Shares Bought by Raymond James & Associates

Raymond James & Associates lifted its stake in shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) by 3.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,691 shares of the company’s stock after buying an additional 2,216 shares during the quarter. Raymond James & Associates owned about 0.17% of Pacira Pharmaceuticals worth $3,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in PCRX. Consonance Capital Management LP increased its position in shares of Pacira Pharmaceuticals by 16.1% during the fourth quarter. Consonance Capital Management LP now owns 1,602,334 shares of the company’s stock valued at $73,147,000 after buying an additional 222,200 shares during the period. HealthCor Management L.P. increased its position in shares of Pacira Pharmaceuticals by 8.6% during the fourth quarter. HealthCor Management L.P. now owns 2,800,000 shares of the company’s stock valued at $127,820,000 after buying an additional 221,960 shares during the period. Two Sigma Advisers LP increased its position in shares of Pacira Pharmaceuticals by 918.8% during the fourth quarter. Two Sigma Advisers LP now owns 221,076 shares of the company’s stock valued at $10,092,000 after buying an additional 199,376 shares during the period. Renaissance Technologies LLC increased its position in shares of Pacira Pharmaceuticals by 36.2% during the fourth quarter. Renaissance Technologies LLC now owns 509,900 shares of the company’s stock valued at $23,277,000 after buying an additional 135,400 shares during the period. Finally, Two Sigma Investments LP increased its position in shares of Pacira Pharmaceuticals by 195.8% during the fourth quarter. Two Sigma Investments LP now owns 162,121 shares of the company’s stock valued at $7,401,000 after buying an additional 107,321 shares during the period.

How to Become a New Pot Stock Millionaire

In other news, CEO David M. Stack sold 28,885 shares of the stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.60% of the company’s stock.

NASDAQ:PCRX opened at $33.30 on Friday. Pacira Pharmaceuticals Inc. has a 52 week low of $26.95 and a 52 week high of $52.47. The company has a debt-to-equity ratio of 0.99, a quick ratio of 6.22 and a current ratio of 6.96. The company has a market cap of $1,200.99, a PE ratio of -57.41 and a beta of 1.77.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The firm had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. equities analysts predict that Pacira Pharmaceuticals Inc. will post -0.57 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on the stock. JPMorgan Chase reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Thursday, January 4th. HC Wainwright set a $55.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, January 4th. Canaccord Genuity set a $46.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 4th. Royal Bank of Canada set a $54.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 4th. Finally, Leerink Swann began coverage on shares of Pacira Pharmaceuticals in a report on Tuesday, January 2nd. They issued a “market perform” rating and a $46.00 price objective on the stock. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the stock. Pacira Pharmaceuticals has an average rating of “Hold” and a consensus price target of $44.06.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3340648/pacira-pharmaceuticals-inc-pcrx-shares-bought-by-raymond-james-associates.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MaidSafeCoin  Hits One Day Trading Volume of $1.94 Million
MaidSafeCoin Hits One Day Trading Volume of $1.94 Million
$0.48 Earnings Per Share Expected for State Bank Financial  This Quarter
$0.48 Earnings Per Share Expected for State Bank Financial This Quarter
Quantstamp  Hits Market Cap of $102.59 Million
Quantstamp Hits Market Cap of $102.59 Million
Critical Contrast: Generac  and Franklin Electric
Critical Contrast: Generac and Franklin Electric
Head-To-Head Analysis: Avis Budget Group  and Ryder
Head-To-Head Analysis: Avis Budget Group and Ryder
Critical Comparison: GCP Applied Technologies  and Its Competitors
Critical Comparison: GCP Applied Technologies and Its Competitors


Leave a Reply

© 2006-2018 Ticker Report. Google+.